Your browser doesn't support javascript.
loading
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: General view of the pathogens' antibacterial susceptibility.
Yanagihara, Katsunori; Kadota, Junichi; Aoki, Nobuki; Matsumoto, Tetsuya; Yoshida, Masaki; Yagisawa, Morimasa; Oguri, Toyoko; Sato, Junko; Ogasawara, Kazuhiko; Wakamura, Tomotaro; Sunakawa, Keisuke; Watanabe, Akira; Iwata, Satoshi; Kaku, Mitsuo; Hanaki, Hideaki; Ohsaki, Yoshinobu; Watari, Tomohisa; Toyoshima, Eri; Takeuchi, Kenichi; Shiokoshi, Mayumi; Takeda, Hiroaki; Miki, Makoto; Kumagai, Toshio; Nakanowatari, Susumu; Takahashi, Hiroshi; Utagawa, Mutsuko; Nishiya, Hajime; Kawakami, Sayoko; Kobayashi, Nobuyuki; Takasaki, Jin; Mezaki, Kazuhisa; Konosaki, Hisami; Aoki, Yasuko; Yamamoto, Yumiko; Shoji, Michi; Goto, Hajime; Saraya, Takeshi; Kurai, Daisuke; Okazaki, Mitsuhiro; Niki, Yoshihito; Yoshida, Koichiro; Kawana, Akihiko; Saionji, Katsu; Fujikura, Yuji; Miyazawa, Naoki; Kudo, Makoto; Sato, Yoshimi; Yamamoto, Masaki; Yoshida, Takashi; Nakamura, Masahiko.
Afiliação
  • Yanagihara K; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Nagasaki University School of Medicine, Nagasaki, Japan. Electronic address: karyo@jc4.so-net.ne.jp.
  • Kadota J; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Oita University Faculty of Medicine, Oita, Japan.
  • Aoki N; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Shinrakuen Hospital, Niigata, Japan.
  • Matsumoto T; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Yoshida M; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Yagisawa M; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Oguri T; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Sato J; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Ogasawara K; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Wakamura T; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Sunakawa K; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Watanabe A; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Iwata S; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Kaku M; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and The Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Hanaki H; The Kitasato Institute, Tokyo, Japan.
  • Ohsaki Y; Asahikawa Medical University, Hokkaido, Japan.
  • Watari T; Asahikawa Medical University, Hokkaido, Japan.
  • Toyoshima E; Asahikawa Medical University, Hokkaido, Japan.
  • Takeuchi K; Iwate Prefectural Central Hospital, Iwate, Japan.
  • Shiokoshi M; Iwate Prefectural Central Hospital, Iwate, Japan.
  • Takeda H; Saiseikai Yamagata Saisei Hospital, Yamagata, Japan.
  • Miki M; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
  • Kumagai T; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
  • Nakanowatari S; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
  • Takahashi H; Saka General Hospital, Miyagi, Japan.
  • Utagawa M; Saka General Hospital, Miyagi, Japan.
  • Nishiya H; Teikyo University School of Medicine, Tokyo, Japan.
  • Kawakami S; Teikyo University School of Medicine, Tokyo, Japan.
  • Kobayashi N; National Center for Global Health and Medicine, Tokyo, Japan.
  • Takasaki J; National Center for Global Health and Medicine, Tokyo, Japan.
  • Mezaki K; National Center for Global Health and Medicine, Tokyo, Japan.
  • Konosaki H; National Center for Global Health and Medicine, Tokyo, Japan.
  • Aoki Y; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Yamamoto Y; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Shoji M; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Goto H; Kyorin University Hospital, Tokyo, Japan.
  • Saraya T; Kyorin University Hospital, Tokyo, Japan.
  • Kurai D; Kyorin University Hospital, Tokyo, Japan.
  • Okazaki M; Kyorin University Hospital, Tokyo, Japan.
  • Niki Y; Showa University, School of Medicine, Tokyo, Japan.
  • Yoshida K; Showa University, School of Medicine, Tokyo, Japan.
  • Kawana A; National Defense Medical College, Saitama, Japan.
  • Saionji K; National Defense Medical College, Saitama, Japan.
  • Fujikura Y; National Defense Medical College, Saitama, Japan.
  • Miyazawa N; Yokohama City University Hospital, Kanagawa, Japan.
  • Kudo M; Yokohama City University Hospital, Kanagawa, Japan.
  • Sato Y; Yokohama City University Hospital, Kanagawa, Japan.
  • Yamamoto M; Yokohama City University Hospital, Kanagawa, Japan.
  • Yoshida T; Toyama Prefectural Central Hospital, Toyama, Japan.
  • Nakamura M; Toyama Prefectural Central Hospital, Toyama, Japan.
J Infect Chemother ; 21(6): 410-20, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25817352
ABSTRACT
The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from patients in Japan, was conducted by Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases and Japanese Society for Clinical Microbiology in 2010. The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period from January and April 2010 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical and Laboratory Standard Institutes using maximum 45 antibacterial agents. Susceptibility testing was evaluable with 954 strains (206 Staphylococcus aureus, 189 Streptococcus pneumoniae, 4 Streptococcus pyogenes, 182 Haemophilus influenzae, 74 Moraxella catarrhalis, 139 Klebsiella pneumoniae and 160 Pseudomonas aeruginosa). Ratio of methicillin-resistant S. aureus was as high as 50.5%, and those of penicillin-intermediate and -resistant S. pneumoniae were 1.1% and 0.0%, respectively. Among H. influenzae, 17.6% of them were found to be ß-lactamase-non-producing ampicillin (ABPC)-intermediately resistant, 33.5% to be ß-lactamase-non-producing ABPC-resistant and 11.0% to be ß-lactamase-producing ABPC-resistant strains. Extended spectrum ß-lactamase-producing K. pneumoniae and multi-drug resistant P. aeruginosa with metallo ß-lactamase were 2.9% and 0.6%, respectively. Continuous national surveillance of antimicrobial susceptibility of respiratory pathogens is crucial in order to monitor changing patterns of susceptibility and to be able to update treatment recommendations on a regular basis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Bactérias / Infecções Bacterianas / Farmacorresistência Bacteriana / Antibacterianos Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Bactérias / Infecções Bacterianas / Farmacorresistência Bacteriana / Antibacterianos Idioma: En Ano de publicação: 2015 Tipo de documento: Article